Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
68 hedge funds and large institutions have $346M invested in Paratek Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 7 closing their positions.
429% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 7
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
79% more funds holding
Funds holding: 38 → 68 (+30)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
18% more capital invested
Capital invested by funds: $292M → $346M (+$54.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$19.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.8M |
| 4 |
BBHC
Brown Brothers Harriman & Co
New York
|
+$10.4M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$8.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$5.41M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$901K |
| 3 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$605K |
| 4 |
SIM
Spark Investment Management
New York
|
-$434K |
| 5 |
Goldman Sachs
New York
|
-$365K |
PRTK Hedge Fund Activity: Q2 2015 in Review
68 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2015, worth a combined $346M — up 18% from $292M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new PRTK positions and 7 closed out — a net gain of 30 holders — while 18 added to existing stakes and 9 trimmed.
The largest buyer was Tekla Capital Management, opening a new position worth an estimated $19.6M. The largest seller was Baupost Group, cutting an estimated $5.41M.
- 68 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2015, up from 38 in Q1 2015.
- Funds reported $346M of Paratek Pharmaceuticals, Inc. stock for Q2 2015, up 18% quarter-over-quarter.
- 37 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2015 and 7 closed out, a net change of +30 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2015 was Tekla Capital Management, an estimated $19.6M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q2 2015 was Baupost Group, an estimated $5.41M sold.
Based on aggregated 13F filings for Q2 2015.